Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.

Description: In this session actuarial and benefit design issues of various health care reform proposals will be identified. An update on task force activities will be presented. The relative richness of benefits will be discussed. Key benefit components such as mental illness coverages will be featured. From Record of Society of Actuaries Vol. 20, No. 3A.

Description: This presents the results of a May 2010 survey by the Society of Actuaries SOA asking members of the SOA Health Section for their opinions on ways to bend the cost curve in light of the Patient Protection and Affordable Care Act ACA, the new health reform law passed in March 2010.

Description: 2001 SOA Annual Meeting, New Orleans. Health care cost trends have substantially increased in the past two years. Panelists discussed the factors contributing to these increased trends, the prospect for further increases in the future, and national health care issues.

Description: Panelists present the positions being staked out by the political parties, the likelihood of passage of any of the proposed legislation, and the potential impacts on the health care market of the various proposals. From the Record of the Society of Actuaries, Volume 27, No. 3, Session 131PD.

Description: Presented at October 2000 Annual Meeting. The panel presents the status of recent legislative proposals and current election debates, and then focuses more attention on the potential longer-term directions for the health-care system.

Description: This research report examines the potential implications of the risk mitigation programs – risk adjustment, reinsurance, and risk corridors – established under The Patient Protection and Affordable Care Act.

Description: Risk adjusters were first used for the Y2K reimbursements to Medicare+Choice laws. How did plans fare? What was the financial impact to the Medicare program? What changes are expected for the future? From Record of Society of Actuaries, Volume 26, No. 1. From Record of Society of Actuaries, Volume 26, No. 1: Las Vegas Spring Meeting, May 22-24, 2000, Session 125PD.

Description: A discussion of fraud and abuse in the Medicare payment system, and steps to address these problems.

Description: Update on the potential impact of national health law legislation, and discussion of the influence of inflation on both the relation between actual and expected claims, and the design of new benefits and administrative procedures. This presentation was made at the 1975 SOA Los Angeles Spring Meeting.